The company switched from "Phase 1" terminology to "Early Phase 1" in their announcement on the 11th May, I am hoping that this does not mean there is a second Phase 1 trial to follow the "early" Phase 1 Trial - from your comment it makes me think there wont be but would love to hear it from the horses mouth. The company also said in there announcement on 11th May: A complete overview of the clinical development plan to support the neurology treatment indications forEmtinB will be provided in a separate announcement in the coming days. I have been very vocal on here about my frustration towards management missing key deadlines, misleading shareholders, and deceitful behavior, - add this to the laundry list.
Initially we were told after last years options we would be fully funded until completion of Phase 1 trials, from memory we had approx. $15m at the time. As per the last quarterly we are in a "strong" cash position with 7.9m in the bank, so about half that money gone, albeit with NEUROLOGY trials to start soon... Where I am a bit concerned is with the Glaucoma trials, from what I can see the company hasn't made any mention of these trials since the 24/03/22 - and an update on these trials was omitted from the quarterly??? According to the investor presentation on that date Glaucoma trials are due to start in 2H 2022...
I really do hope Management has the competence to deliver Ph1 Neurology AND Glaucoma trials with that $7.9m cash we had as at 31.03.22. Raising capital in this environment will be a nightmare - would be good for us loyal shareholders to actually see some progress which is what we need to get back in the green - perhaps now most of you are in the red as well its time to start asking some questions of the management?
Holding, unhappily
- Forums
- ASX - By Stock
- Ann: Ethics Approval Granted for Early-Phase Clinical Trial
The company switched from "Phase 1" terminology to "Early Phase...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NSB (ASX) to my watchlist
|
|||||
Last
3.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.64M |
Open | High | Low | Value | Volume |
4.0¢ | 4.0¢ | 3.9¢ | $1.493K | 37.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 29149 | 3.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.1¢ | 125000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 29149 | 0.039 |
2 | 400000 | 0.035 |
1 | 300000 | 0.034 |
1 | 33332 | 0.030 |
1 | 71036 | 0.028 |
Price($) | Vol. | No. |
---|---|---|
0.041 | 125000 | 1 |
0.042 | 13500 | 1 |
0.046 | 25000 | 1 |
0.050 | 229084 | 3 |
0.051 | 75976 | 1 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
NSB (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online